Xenon Pharmaceuticals Inc.

XENE

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Dec 15, 2025

Drug Pipeline

Drug Name	Phase	Indication	Designations
Azetukalner	Phase 3	Major Depressive Disorder	-
Placebo	Phase 3	Focal Onset Seizures	-
XEN1101	Phase 3	Primary Generalized Tonic-Clonic Seizures	-
XPF-002	Phase 2	Postherpetic Neuralgia	-
XPF-005	Phase 2	Acne Vulgaris	-
XEN1101 10 mg	Phase 2	Major Depressive Disorder	-
XPF-001	Phase 2	Dental Pain	-

Catalyst Timeline

5 upcoming, 0 past

⭐Phase 3Next

December 2025~XEN1101

Primary completion for XEN1101 trial (NCT05614063) in Focal Onset Seizures

⭐Phase 3

December 2025~Placebo

Primary completion for Placebo trial (NCT05614063) in Focal Onset Seizures

⭐Phase 3

August 2026~Azetukalner

Primary completion for Azetukalner trial (NCT06775379) in Major Depressive Disorder

⭐Phase 3

October 2026~XEN1101

Primary completion for XEN1101 trial (NCT05716100) in Focal Onset Seizures

⭐Phase 3

October 2026~Placebo

Primary completion for Placebo trial (NCT05716100) in Focal Onset Seizures

Regulatory Approvals

XENE News

XENE

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Dec 15, 2025

Drug Pipeline

Drug Name	Phase	Indication	Designations
Azetukalner	Phase 3	Major Depressive Disorder	-
Placebo	Phase 3	Focal Onset Seizures	-
XEN1101	Phase 3	Primary Generalized Tonic-Clonic Seizures	-
XPF-002	Phase 2	Postherpetic Neuralgia	-
XPF-005	Phase 2	Acne Vulgaris	-
XEN1101 10 mg	Phase 2	Major Depressive Disorder	-
XPF-001	Phase 2	Dental Pain	-